Article info
PDFTherapeutics
Randomised controlled trial
Eplerenone reduces risk of cardiovascular death or hospitalisation in heart failure patients with reduced ejection fraction
- Correspondence to Mihai Gheorghiade
Cardiovascular Center for Drug Development, Duke University, 645 North Michigan Avenue, Suite 1006, Chicago, IL 60611, USA; m-gheorghiade{at}northwestern.edu
Citation
Eplerenone reduces risk of cardiovascular death or hospitalisation in heart failure patients with reduced ejection fraction
Publication history
- First published May 10, 2011.
Online issue publication
October 25, 2017
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions